Aktis Oncology

Historical price data

Aktis Oncology's mission is to transform cancer care by developing next-generation targeted alpha radiopharmaceuticals for solid tumors historically beyond the reach of this modality. The company's core innovation is a proprietary miniprotein radioconjugate platform engineered for deep tumor penetration, rapid systemic clearance, and high tumor residence time. Since its 2019 founding, Aktis has advanced a pipeline led by AKY-1189 (Nectin-4) into Phase 1b and AKY-2519 (B7-H3) into IND-enabling studies, culminating in a successful public listing in 2024. Its strategy is to leverage its platform to build a broad pipeline addressing large-market epithelial cancers.

A proprietary miniprotein radioconjugate platform engineered to deliver potent alpha-emitting isotopes (e.g., Actinium-225) to tumor cells with high specificity, deep tissue penetration, rapid systemic clearance, and integrated theranostic capability.